F
Fred R. Hirsch
Researcher at University of Colorado Denver
Publications - 401
Citations - 33536
Fred R. Hirsch is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Lung cancer & Large Hadron Collider. The author has an hindex of 85, co-authored 362 publications receiving 31524 citations. Previous affiliations of Fred R. Hirsch include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006
Journal ArticleDOI
November - Lung Cancer Awareness Month!
TL;DR: An international multidisciplinary workshop was held, including representatives from the patients’ advocacy groups, with the goal of identifying barriers for improvements for early stage disease, including perception of stigma and nihilism in the public, and slow accrual to clinical trials.
Journal ArticleDOI
PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients
Sooyun Tavolacci,Philip C. Mack,Jorge Gomez,Nicholas C. Rohs,Ananda M. Rodilla,Diego de Miguel Perez,Juan Manuel Carreño,Chin-Yuan Hsu,Jazz Cagan,Christian Rolfo,Amy P. Moore,Rachel I. Brody,J. King,David E. Gerber,Claudia I. Henschke,David F. Yankelevitz,John D. Minna,P. Bunn,Adolfo García-Sastre,Florian Krammer,Yu Shyr,Fred R. Hirsch +21 more
Journal ArticleDOI
Bone Marrow Examination in Small Cell Lung Cancer
TL;DR: The question whether examination of bone marrow is necessary for patients with small cell lung cancer has recently been raised and has also been raised by Campling and associates.
Journal ArticleDOI
Abstract CT205: A phase I/Ib trial of intratumoral Poly-ICLC in resectable malignant pleural mesothelioma
Bailey Gleason Fitzgerald,Thomas U. Marron,Robert Sweeney,Jorge García-Andrade Gómez,N. M. Hall,Daniel O'Grady,Christian Rolfo,Rajwanth R. Veluswamy,Deborah B. Doroshow,John Mandeli,David F. Yankelevitz,Nina Bhardwaj,Sacha Gnjatic,Fred R. Hirsch,Miriam Merad,Alexander M. Tsankov,Raja M. Flores,Andrea S. Wolf +17 more
TL;DR: It is hypothesize that injection of poly-ICLC prior to surgical resection may activate intratumoral (IT) DC1s, increase tumor antigen presentation to cytotoxic T cells, and induce tumor-specific immune surveillance, as well as characterization of immune parameters such as local B cell specificity.